Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Genentech down on Avastin vote

DNA fell $6.49 to $66.29 on Wednesday after FDA's Oncologic Drugs Advisory

Read the full 122 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE